IRTC heads into the back half of June with a familiar tension: a sharp price recovery running straight into a wall of analyst target cuts that have yet to stop.
The stock gained 6.2% on Tuesday and is up nearly 8% on the week to close at $113.83. That rebound trims a 5.7% monthly loss and comes ahead of a Q2 earnings date pencilled in for August 6. The move looks more like a technical bounce than a re-rating — and the Street's recent behaviour backs that read up.
The analyst direction is unmistakably bearish on valuation, even if the ratings themselves hold. JPMorgan cut its target from $215 to $175 on May 1, staying Overweight. BofA Securities lowered from $225 to $180 while keeping Buy. Canaccord Genuity trimmed from $198 to $180 in May, then cut again to $152 just last week — a meaningful step down that now sits below the current price by around $38 of implied upside. The consensus mean of $178.93 still suggests room to run from $113.83, but the direction of travel on individual targets has been consistently lower since late April. BTIG did reiterate its $185 Buy on Tuesday without a target move, offering the mildest of counterweights. The bull case rests on 17-18% revenue growth in 2026, the Zio System's durable reimbursement position, and a path toward $1 billion in revenue and 15% EBITDA by 2027. Bears point to reimbursement rate risk, rising competition, and the fact that the PE multiple — still at 216x — leaves virtually no margin for execution misses.
Short positioning is a secondary angle this week, not the primary one. Short interest runs at 9.5% of the free float — meaningful, but it edged down roughly 3.6% over the past week and has been broadly flat at this level for a month. Borrowing costs are cheap at 0.46% and have barely moved. Borrow availability is running at over 1,000% — more than ten shares available to lend for every one currently borrowed — so there is no squeeze mechanism building in the lending market. The ORTEX short score of 54.1 is moderate and has drifted slightly lower over the past ten days, consistent with shorts gently covering into the price recovery rather than pressing new positions. Options tell a slightly different story: the put/call ratio of 1.69 is above its 20-day average of 1.56, signalling that options traders are carrying more downside protection than usual even as the stock rallies. The z-score of 0.6 makes this elevated but not extreme.
One ownership detail is worth flagging. FMR (Fidelity) added 733,195 shares in the period ending May 29, building to 1.36 million shares or 4.1% of the company — a material addition from a significant manager. Millennium Management also added 781,638 shares in Q1. On the other side, insider activity has been one-directional: every transaction in the trailing 90 days has been a sale, from the Chief Risk Officer, the Chief Accounting Officer, the Independent Chairman, the CTO, and the Chief Medical Officer. None of the individual trades is large enough on its own to flag as a primary signal — the largest, the Chairman's cluster on May 11, totalled around $626,000 across multiple transactions — but the uniformity of direction is notable at a time when the stock is trading roughly 36% below the analyst consensus target.
The next clear test is Q2 earnings on August 6. Between now and then, the question worth watching is whether analyst targets stabilise at current levels or continue drifting lower — any further cuts from the firms already below the current price would start to make the consensus mean look more aspirational than achievable.
See the live data behind this article on ORTEX.
Open IRTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
